A5045944117- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Renal cell carcinoma treatment
- Neuroendocrine Tumor Research Advances
- Melanoma and MAPK Pathways
- 3D Printing in Biomedical Research
- Tuberous Sclerosis Complex Research
- Neonatal Respiratory Health Research
- Law, AI, and Intellectual Property
- Pancreatic and Hepatic Oncology Research
- Advanced Breast Cancer Therapies
- Chronic Lymphocytic Leukemia Research
- Medical Imaging and Pathology Studies
- Lung Cancer Research Studies
- Cutaneous Melanoma Detection and Management
- Respiratory viral infections research
- Single-cell and spatial transcriptomics
- Tracheal and airway disorders
- HER2/EGFR in Cancer Research
- Vascular Tumors and Angiosarcomas
- Renal and related cancers
- Cancer Treatment and Pharmacology
The Netherlands Cancer Institute
2015-2021
Oncode Institute
2019-2021
Dutch Cancer Society
2018
Center for Personalized Cancer Treatment
2016-2017
Resource14 January 2019Open Access Transparent process Long-term expanding human airway organoids for disease modeling Norman Sachs Oncode Institute, Hubrecht Institute-KNAW and UMC Utrecht, The Netherlands Search more papers by this author Angelos Papaspyropoulos Domenique D Zomer-van Ommen Wilhelmina Children's Hospital Inha Heo Lena Böttinger Dymph Klay St. Antonius Nieuwegein, Fleur Weeber Cancer Amsterdam, Guizela Huelsz-Prince FOM Institute AMOLF, Nino Iakobachvili Maastricht...
There is a clear and unmet clinical need for biomarkers to predict responsiveness chemotherapy cancer. We developed an in vitro test based on patient-derived tumor organoids (PDOs) from metastatic lesions identify nonresponders standard-of-care colorectal cancer (CRC). In prospective study, we show the feasibility of generating testing PDOs evaluation sensitivity chemotherapy. Our PDO predicted response biopsied lesion more than 80% patients treated with irinotecan-based therapies without...
Significance Chemotherapy has been proven in clinical studies to improve overall survival significantly. Unfortunately, there is a significant degree of heterogeneity tumor chemosensitivity, often resulting unnecessary treatment and needless exposure toxic side-effects. A platform needed that can identify preemptively which patients will or not benefit from treatment. Tumor organoids, 3D cultures cancer cells, present such an individualized platform. In this study we demonstrate organoid be...
Research Article23 June 2015Open Access Source Data Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient derived xenografts Kristel Kemper Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, Search for more papers by this author Oscar Krijgsman Paulien Cornelissen-Steijger Aida Shahrabi Fleur Weeber Ji-Ying Song Experimental Animal Pathology, Thomas Kuilman Daniel J Vis Computational Biology, Lodewyk F Wessels Emile E Voest Ton NM...
The therapeutic landscape of melanoma is improving rapidly. Targeted inhibitors show promising results, but drug resistance often limits durable clinical responses. There a need for in vivo systems that allow mechanistic studies and (combinatorial) treatment optimization. Therefore, we established large collection patient-derived xenografts (PDXs), derived from BRAFV600E, NRASQ61, or BRAFWT/NRASWT metastases prior to with BRAF inhibitor after had occurred. Taking advantage PDXs as limitless...
The discovery of novel biomarkers that predict treatment response in advanced cancer patients requires acquisition high-quality tumor samples. As evolves over time, tissue is ideally obtained before the start each treatment. Preferably, samples are freshly frozen to allow analysis by next-generation DNA/RNA sequencing (NGS) but also for making other emerging systematic techniques such as proteomics and metabolomics possible. Here, we describe first 469 image-guided biopsies collected a large...
Gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) is a poorly understood disease with limited treatment options. A better understanding of this would greatly benefit from the availability representative preclinical models. Here, we present potential tumor organoids, three-dimensional cultures cells, to model GEP-NEC. We established three GEP-NEC organoid lines, originating stomach and colon, characterized them using DNA sequencing immunohistochemistry. Organoids largely resembled...
Abstract Organoids are self-organizing 3D structures grown from stem cells that recapitulate essential aspects of organ structure and function. Here we describe a method to establish long-term-expanding human airway organoids broncho-alveolar biopsies or lavage material. The pseudostratified organoid epithelium consists basal cells, functional multi-ciliated mucus-producing goblet CC10-secreting club cells. Airway derived cystic fibrosis (CF) patients allow assessment CFTR function in an...
In this study, our aim was to identify molecular aberrations predictive for response everolimus, an mTOR inhibitor, regardless of tumor type.To generate hypotheses about potential markers sensitivity inhibition, drug and genomic profiles 835 cell lines were analyzed. Subsequently, a multicenter study conducted. Patients with advanced solid tumors lacking standard care treatment options included underwent pre-treatment biopsy enable DNA sequencing 1,977 genes, derive copy number determine...
Abstract Introduction: Early signs of clinical activity are an important factor in the decision to advance development novel targeted drugs. Response Evaluation Criteria In Solid Tumors (RECIST) has limited value however, as many patients with relatively slowly growing tumors will end up Stable Disease (SD) group, obscuring distinction between a slow natural course disease or treatment effect. Furthermore, when determining therapeutic efficacy across tumor types using progression free...